Cargando…
pH-responsive antibodies for therapeutic applications
Therapeutic antibodies are instrumental in improving the treatment outcome for certain disease conditions. However, to enhance their efficacy and specificity, many efforts are continuously made. One of the approaches that are increasingly explored in this field are pH-responsive antibodies capable o...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821552/ https://www.ncbi.nlm.nih.gov/pubmed/33482842 http://dx.doi.org/10.1186/s12929-021-00709-7 |
_version_ | 1783639446227255296 |
---|---|
author | Klaus, Tomasz Deshmukh, Sameer |
author_facet | Klaus, Tomasz Deshmukh, Sameer |
author_sort | Klaus, Tomasz |
collection | PubMed |
description | Therapeutic antibodies are instrumental in improving the treatment outcome for certain disease conditions. However, to enhance their efficacy and specificity, many efforts are continuously made. One of the approaches that are increasingly explored in this field are pH-responsive antibodies capable of binding target antigens in a pH-dependent manner. We reviewed suitability and examples of these antibodies that are functionally modulated by the tumor microenvironment. Provided in this review is an update about antigens targeted by pH-responsive, sweeping, and recycling antibodies. Applicability of the pH-responsive antibodies in the engineering of chimeric antigen receptor T-cells (CAR-T) and in improving drug delivery to the brain by the enhanced crossing of the blood–brain barrier is also discussed. The pH-responsive antibodies possess strong treatment potential. They emerge as next-generation programmable engineered biologic drugs that are active only within the targeted biological space. Thus, they are valuable in targeting acidified tumor microenvironment because of improved spatial persistence and reduced on-target off-tumor toxicities. We predict that the programmable pH-dependent antibodies become powerful tools in therapies of cancer. |
format | Online Article Text |
id | pubmed-7821552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78215522021-01-25 pH-responsive antibodies for therapeutic applications Klaus, Tomasz Deshmukh, Sameer J Biomed Sci Review Therapeutic antibodies are instrumental in improving the treatment outcome for certain disease conditions. However, to enhance their efficacy and specificity, many efforts are continuously made. One of the approaches that are increasingly explored in this field are pH-responsive antibodies capable of binding target antigens in a pH-dependent manner. We reviewed suitability and examples of these antibodies that are functionally modulated by the tumor microenvironment. Provided in this review is an update about antigens targeted by pH-responsive, sweeping, and recycling antibodies. Applicability of the pH-responsive antibodies in the engineering of chimeric antigen receptor T-cells (CAR-T) and in improving drug delivery to the brain by the enhanced crossing of the blood–brain barrier is also discussed. The pH-responsive antibodies possess strong treatment potential. They emerge as next-generation programmable engineered biologic drugs that are active only within the targeted biological space. Thus, they are valuable in targeting acidified tumor microenvironment because of improved spatial persistence and reduced on-target off-tumor toxicities. We predict that the programmable pH-dependent antibodies become powerful tools in therapies of cancer. BioMed Central 2021-01-22 /pmc/articles/PMC7821552/ /pubmed/33482842 http://dx.doi.org/10.1186/s12929-021-00709-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Klaus, Tomasz Deshmukh, Sameer pH-responsive antibodies for therapeutic applications |
title | pH-responsive antibodies for therapeutic applications |
title_full | pH-responsive antibodies for therapeutic applications |
title_fullStr | pH-responsive antibodies for therapeutic applications |
title_full_unstemmed | pH-responsive antibodies for therapeutic applications |
title_short | pH-responsive antibodies for therapeutic applications |
title_sort | ph-responsive antibodies for therapeutic applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821552/ https://www.ncbi.nlm.nih.gov/pubmed/33482842 http://dx.doi.org/10.1186/s12929-021-00709-7 |
work_keys_str_mv | AT klaustomasz phresponsiveantibodiesfortherapeuticapplications AT deshmukhsameer phresponsiveantibodiesfortherapeuticapplications |